Thr58

Site Information
EANEGsktLQRNRKM SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 9424114

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 5 ) , Jurkat (T lymphocyte) ( 2 , 3 , 4 ) , Vero E6-S ('epithelial, kidney') ( 1 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mulhern D (2012) CST Curation Set: 13827; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
3	Mulhern D (2012) CST Curation Set: 13828; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
4	Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
5	Guo A (2010) CST Curation Set: 6269; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info